FDA
-
-
-
-
-
-
-
NeuroPace receives FDA approval for AI-driven epilepsy care tool
-
-
-
-
-
-
-
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on NeuroPace Inc (NPCE)
-
-
-
-
-
-
-
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
NeuroPace (NPCE) Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
-
-
-
-
-
-
-
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway
-
328,347 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

